These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 29656444

  • 1. Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.
    Quirant-Sánchez B, Hervás-García JV, Teniente-Serra A, Brieva L, Moral-Torres E, Cano A, Munteis E, Mansilla MJ, Presas-Rodriguez S, Navarro-Barriuso J, Ramo-Tello C, Martínez-Cáceres EM.
    CNS Neurosci Ther; 2018 Dec; 24(12):1175-1184. PubMed ID: 29656444
    [Abstract] [Full Text] [Related]

  • 2. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.
    Teniente-Serra A, Hervás JV, Quirant-Sánchez B, Mansilla MJ, Grau-López L, Ramo-Tello C, Martínez-Cáceres EM.
    CNS Neurosci Ther; 2016 Jul; 22(7):584-92. PubMed ID: 27080413
    [Abstract] [Full Text] [Related]

  • 3. Response to Fingolimod in Multiple Sclerosis Patients Is Associated with a Differential Transcriptomic Regulation.
    Sánchez-Sanz A, Muñoz-Viana R, Sabín-Muñoz J, Moreno-Torres I, Brea-Álvarez B, Rodríguez-De la Fuente O, García-Merino A, Sánchez-López AJ.
    Int J Mol Sci; 2024 Jan 23; 25(3):. PubMed ID: 38338652
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    Kürtüncü M, Yılmaz V, Akçay Hİ, Türkoğlu R, Altunrende B, Çınar SA, Ulusoy C, Gündüz T, İçöz S, Kasap M, Çalışkan Z, Ötünç G, Eraksoy M, Tüzün E.
    J Neuroimmunol; 2019 Dec 15; 337():577065. PubMed ID: 31526917
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
    Angerer IC, Hecker M, Koczan D, Roch L, Friess J, Rüge A, Fitzner B, Boxberger N, Schröder I, Flechtner K, Thiesen HJ, Winkelmann A, Meister S, Zettl UK.
    CNS Neurosci Ther; 2018 Mar 15; 24(3):193-201. PubMed ID: 29314605
    [Abstract] [Full Text] [Related]

  • 8. Study of the NR4A family gene expression in patients with multiple sclerosis treated with Fingolimod.
    Montarolo F, Perga S, Martire S, Brescia F, Caldano M, Lo Re M, Panzica G, Bertolotto A.
    Eur J Neurol; 2019 Apr 15; 26(4):667-672. PubMed ID: 30565812
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
    Esposito F, Ferrè L, Clarelli F, Rocca MA, Sferruzza G, Storelli L, Radaelli M, Sangalli F, Moiola L, Colombo B, Martinelli Boneschi F, Comi G, Filippi M, Martinelli V.
    J Neurol; 2018 Apr 15; 265(4):896-905. PubMed ID: 29435643
    [Abstract] [Full Text] [Related]

  • 12. A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression.
    Dominguez-Mozo MI, Galán V, Ramió-Torrentà L, Quiroga A, Quintana E, Villar LM, Costa-Frossard L, Fernández-Velasco JI, Villarrubia N, Garcia-Martinez MA, Arroyo R, Alvarez-Lafuente R.
    Front Immunol; 2024 Apr 15; 15():1384411. PubMed ID: 38911861
    [Abstract] [Full Text] [Related]

  • 13. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Koch-Henriksen N, Magyari M, Sellebjerg F, Soelberg Sørensen P.
    Mult Scler; 2017 Feb 15; 23(2):234-241. PubMed ID: 27055806
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.
    Cascione M, Tenenbaum N, Wendt J, Meng X, Schofield L, Cree BAC, PREFERMS investigators.
    Mult Scler Relat Disord; 2018 Oct 15; 25():50-56. PubMed ID: 30036854
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.